Literature DB >> 31356759

True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center.

Shin Ju Oh1, Chang Kyun Lee1, Youn-Wha Kim2, Su Jin Jeong3, Yoo Min Park1, Chi Hyuk Oh1, Jung-Wook Kim1, Hyo Jong Kim1.   

Abstract

Background and aims: The impact of cytomegalovirus (CMV) colitis on long-term outcomes of ulcerative colitis (UC) flares remains controversial.
Methods: A total of 257 UC patients with moderate-to-severe flares were observed for a mean follow-up of 41.2 months. CMV colitis was defined as histopathologic confirmation of CMV inclusions obtained from macroscopic endoscopic lesions in patients with UC flares. An independent gastrointestinal pathologist prospectively reviewed all specimens. A poor outcome was defined as any of hospitalization, colectomy or death during the follow-up period.
Results: The prevalence of CMV colitis was 14% (36/257) over the 10-year study period (2007-2016). When compared to the controls, patients with CMV colitis were characterized by older age, higher disease activity, endoscopic deep ulcerations and more frequent use of immunosuppressive drugs (all p < .05). In total, 57 outcome events (50 hospitalizations, seven colectomies) were observed among the study population (44.7% in patients with CMV colitis vs. 18.9% in controls). The cumulative probability of a poor outcome was significantly greater in the patients with CMV colitis than in the controls (log-rank test p < .001). In a multivariable analysis, CMV colitis remained as an independent predictor of a poor outcome (hazard ratio; 2.27; 95% confidence interval: 1.12-4.60). Despite a generally favorable response to antiviral therapy (79%), the risk of recurrent CMV colitis remained quite high (57%). Most of the recurrences developed within 8 months (75%). Conclusions: True CMV colitis is a poor prognostic indicator among patients with UC flares. An effective strategy for managing recurrent CMV colitis is urgently needed (KCT0003296).

Entities:  

Keywords:  Ulcerative colitis; cytomegalovirus infections; histology; prognosis; symptom flare up

Mesh:

Substances:

Year:  2019        PMID: 31356759     DOI: 10.1080/00365521.2019.1646798

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  4 in total

Review 1.  Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.

Authors:  Peng-De Lu; Yong-Hua Zhao
Journal:  Chin Med       Date:  2020-02-10       Impact factor: 5.455

2.  Clinical Features, Endoscopic Findings, and Predictive Factors for Mortality in Tissue-Invasive Gastrointestinal Cytomegalovirus Disease between Immunocompetent and Immunocompromised Patients.

Authors:  Panu Wetwittayakhlang; Natthapat Rujeerapaiboon; Poowadon Wetwittayakhlung; Pimsiri Sripongpun; Nannapat Pruphetkaew; Sawangpong Jandee; Naichaya Chamroonkul; Teerha Piratvisuth
Journal:  Gastroenterol Res Pract       Date:  2021-04-06       Impact factor: 2.260

3.  Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study.

Authors:  Hong Yang; Zhihua Ran; Meng Jin; Jia-Ming Qian
Journal:  Gut Liver       Date:  2022-05-25       Impact factor: 4.321

4.  Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis.

Authors:  Shin Ju Oh; Ga Young Shin; Hosim Soh; Jae Gon Lee; Jong Pil Im; Chang Soo Eun; Kang-Moon Lee; Dong Il Park; Dong Soo Han; Hyo Jong Kim; Chang Kyun Lee
Journal:  Intest Res       Date:  2020-08-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.